Coronavirus: Thread

[grarpamp]

> New Hampshire Pharmacies Could Soon

While global pharmacies, even global governments
have been handing out treatment regimens, those
tied to US pharma have not, nor are they doing
much research such as, you decide...


Large, Peer-Reviewed Research Study Proves Ivermectin Works Against COVID-19

https://flccc.substack.com/p/large-peer-reviewed-research-study
https://www.cureus.com/articles/82162-ivermectin-prophylaxis-used-for-covid-19-a-citywide-prospective-observational-study-of-223128-subjects-using-propensity-score-matching

The results are in from the world’s largest study of ivermectin for COVID-19.
Brazil has had over 23 million cases of COVID-19 since the pandemic
began, with a 97% recovery rate.

Researchers in Brazil found that regular use of ivermectin as a
prophylactic agent was associated with significantly reduced COVID-19
infection, hospitalization and mortality rates.

The study was conducted in Itajaí, a port city in the state of Santa
Catarina, between July and December 2020. Study authors include FLCCC
physicians Dr. Flavio Cadegiani and Dr. Pierre Kory. Lead author Dr.
Lucy Kerr was approached by the mayor of Itajaí, after the city began
to experience a severe outbreak of COVID.

The entire population of Itajaí was invited to participate in the
program, which involved a medical visit to compile baseline, personal,
demographic, and medical information. In the absence of
contraindications, ivermectin was offered as a preventative treatment,
to be taken for two consecutive days every 15 days at a dose of 0.2
mg/kg/day.

Of the 223,128 citizens of Itajaí considered for the study, a total of
159,561 subjects elected to participate: over 70% opted to take
ivermectin, and 23% chose not to.
Reduced infection and hospitalization rates

The study found a 44% reduction in COVID-19 infection rate in favor of
the group that took ivermectin (3.5% versus 8.2%).

In cases where a participating citizen of Itajaí became ill with
COVID-19, they were recommended not to use ivermectin or any other
medication in early outpatient treatment. Of those who did become
infected, two equal-sized, highly matched groups (one that used
ivermectin as a prophylaxis and one that did not) were compared. The
regular use of preventative ivermectin led to a 68% reduction in
COVID-19 mortality (0.8% versus 2.6%), and a 56% reduction in
hospitalization rate (1.6% versus 3.3%).
The regular use of preventative ivermectin led to a reduction in
COVID-19 infection, hospitalization and mortality.
Study methods

Since vaccines were not available at the time, and few prophylactic
alternatives existed in the absence of vaccines, Itajaí initiated a
population-wide government program for COVID-19 prophylaxis. This was
a prospective observational study that allowed subjects to self-select
between treatment vs. non-treatment. The use of ivermectin was
optional and based on patients’ preferences, given its benefits as a
preventative agent was unproven.

To ensure the safety of the population, a computer program was
developed to compile and maintain all relevant demographic and
clinical data. All subjects were weighed to be able to accurately
calculate the correct dose of ivermectin. In addition, a brief medical
evaluation was conducted to record past medical history,
comorbidities, use of medications and contraindications to drugs.

The following variables were analyzed and adjusted as confounding
factors or used for balancing and matching groups for propensity score
matching:

    Age

    Sex

    Previous diseases (myocardial infarction and stroke)

    Pre-existing comorbidities (type 2 diabetes, asthma, chronic
obstructive pulmonary disease, hypertension, dyslipidemia,
cardiovascular diseases, cancer [any type], and other pulmonary
diseases)

    Smoking

Patients who presented signs or the diagnosis of COVID-19 before July
7, 2020, were excluded from the sample. Other exclusion criteria
included contraindications to ivermectin and age (subjects below 18
years of age were excluded).

During the study, subjects who were diagnosed with COVID-19 underwent
a specific medical visit to assess clinical manifestations and disease
severity. All subjects with symptoms were recommended not to use
ivermectin, nitazoxanide, hydroxychloroquine, spironolactone, or any
other drug claimed to be effective against COVID-19. The city did not
provide or support any specific pharmacological outpatient treatment
for subjects infected with COVID-19.
Intriguing findings

Interestingly, the group who self-selected to take ivermectin was
older and had more comorbidities than the group who opted for no
treatment. These results show that prophylactic ivermectin may be a
mitigating factor in groups with higher risk of morbidity.
The results show prophylactic ivermectin may be a mitigating factor
for high-risk groups.

The belief that preventative and early treatment therapies would cause
people to relax their caution of remaining socially distanced, leading
to more COVID-19-related infections, is not supported here.

The data demonstrate that using preventative ivermectin significantly
lowers the infection rate, and that benefits outweigh the speculated
increased risk of changes in social behaviors.